Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents No significant financial relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results